Clomiphene citrate

Ovulation induction

Sold as Clomid, Serophene

Updated weekly · checked 10 h ago

$4.65per ea acquisition cost

8NDCs priced

1,483FAERS reports (all-time)

A selective estrogen-receptor modulator taken orally to stimulate ovulation, the longest-established oral fertility drug. Used for anovulation and in some unexplained-infertility protocols.

In a cycle

When it is given

A short course of tablets early in the cycle, usually with follicle monitoring, for timed intercourse or an IUI cycle. Also used in mini-IVF protocols to reduce the injectable load.

Cost

What it actually costs

The national average price a US pharmacy pays to acquire this drug, published by CMS for every priced package. A wholesale floor, not a retail quote.

Package (NDC description)Per unit

Clomiphene Citrate 50 MG Tab
NDC 83390010709 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 72888021358 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 72888021308 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 83390010730 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 70954082530 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 70954082520 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 64980069090 · effective Aug 19, 2026
$4.65
/ ea
Clomiphene Citrate 50 MG Tab
NDC 64980069003 · effective Aug 19, 2026
$4.65
/ ea

Source: CMS National Average Drug Acquisition Cost (NADAC) · as of Aug 19, 2026

Across a whole stimulation cycle, medication typically totals $3,000–$7,000, which is the number that matters for a budget. See the full cycle breakdown or how families pay for it.

FDA label

What the prescribing information says

The current FDA structured product label, as published through openFDA and DailyMed. Excerpted verbatim, not summarised.

What the FDA label approves it for

INDICATIONS AND USAGE Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: Patie

Dosage and administration

DOSAGE AND ADMINISTRATION General Considerations The workup and treatment of candidates for clomiphene citrate therapy should be supervised by physicians experienced in management of gynecologic or endocrine disorders. Patients should be chosen for therapy with clomiphene citrate only after careful diagnostic evaluation (see INDICATIONS AND USAGE ). The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning clomiphene citrate. The therapeutic objective should be balanced with potential risks and discussed with the patient and others involved in the achievement of a pregnancy. Ovulation most often occurs from 5 to 10 days after a course of clomiphene citrate. Coitus should be timed to coincide with the expected time of ovulation. Appropriate tests to determine ovulation may be useful during this time. Recommended Dosage Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tablet) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg clomiphene citrate. A low dosage or duration of treatment course is particular

Warnings and cautions

WARNINGS Visual Symptoms Patients should be advised that blurring or other visual symptoms such as spots or flashes (scintillating scotomata) may occasionally occur during therapy with clomiphene citrate. These visual symptoms increase in incidence with increasing total dose or therapy duration. These visual disturbances are usually reversible; however, cases of prolonged visual disturbance have been reported with some occurring after clomiphene citrate discontinuation. The visual disturbances may be irreversible, especially with increased dosage or duration of therapy. Patients should be warned that these visual symptoms may render such activities as driving a car or operating machinery more hazardous than usual, particularly under conditions of variable lighting. These visual symptoms appear to be due to intensification and prolongation of after-images. Symptoms often first appear or are accentuated with exposure to a brightly lit environment. While measured visual acuity usually has not been affected, a study patient taking 200 mg clomiphene citrate daily developed visual blurring on the 7th day of treatment, which progressed to severe diminution of visual acuity by the 10th day

Contraindications

CONTRAINDICATIONS Hypersensitivity Clomiphene citrate is contraindicated in patients with a known hypersensitivity or allergy to clomiphene citrate or to any of its ingredients. Pregnancy Clomiphene citrate use in pregnant women is contraindicated, as clomiphene citrate does not offer benefit in this population. Available human data do not suggest an increased risk for congenital anomalies above the background population risk when used as indicated. However, animal reproductive toxicology studies showed increased embryo-fetal loss and structural malformations in offspring. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risks to the fetus. (See PRECAUTIONS: Pregnancy ). Liver Disease. Clomiphene citrate therapy is contraindicated in patients with liver disease or a history of liver dysfunction (see also INDICATIONS AND USAGE and ADVERSE REACTIONS ). Abnormal Uterine Bleeding. Clomiphene citrate is contraindicated in patients with abnormal uterine bleeding of undetermined origin (see INDICATIONS AND USAGE ). Ovarian Cysts. Clomiphene citrate is contraindicated in patients with ovarian c

Label for Clomid, source: openFDA structured product labels · as of Sep 5, 2026

Reported adverse events

What has been reported to the FDA

FAERS is a voluntary reporting system. A high count reflects how widely a drug is used and how often people report, not how dangerous it is, and a report is not proof the drug caused the event.

1,483reports, all-time

1,036flagged serious

abortion spontaneous 110
drug exposure during pregnancy 107
nausea 87
off label use 83
headache 81
drug ineffective 74

Source: openFDA FAERS (drug adverse events) · as of Sep 5, 2026

Common questions

About Clomiphene citrate

What is Clomiphene citrate used for in fertility treatment?

A selective estrogen-receptor modulator taken orally to stimulate ovulation, the longest-established oral fertility drug. Used for anovulation and in some unexplained-infertility protocols. A short course of tablets early in the cycle, usually with follicle monitoring, for timed intercourse or an IUI cycle. Also used in mini-IVF protocols to reduce the injectable load.

How is Clomiphene citrate given?

Oral. A short course of tablets early in the cycle, usually with follicle monitoring, for timed intercourse or an IUI cycle. Also used in mini-IVF protocols to reduce the injectable load.

How much does Clomiphene citrate cost?

The national average price a US pharmacy pays to acquire it (CMS NADAC) is $4.65 per ea, effective Aug 19, 2026. That is a wholesale floor, not the cash price you are charged. Across a whole IVF cycle, stimulation medication typically totals $3,000 to $7,000.

Other medications in a cycle

NADAC is the national average price a pharmacy pays to acquire a drug, not the cash price you are charged and not what a clinic bills for a medicated cycle. Dosing here is quoted from the FDA label and is not a prescription: your protocol comes from your clinic. IVFcost.co is an informational data platform, not a medical provider, clinic, or laboratory. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Success rates depend heavily on individual circumstances and are not a promise of any outcome. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the clinic's own current figures.